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Myocardial Remodeling Is Controlled
by Myocyte-Targeted Gene Regulation
of Phosphodiesterase Type 5
Manling Zhang, MD,* Eiki Takimoto, MD, PHD,* Steven Hsu, MD,* Dong I. Lee, PHD,*
Takahiro Nagayama, PHD,* Thomas Danner,* Norimichi Koitabashi, MD, PHD,*
Andreas S. Barth, MD,* Djahida Bedja, MS,† Kathleen L. Gabrielson, PHD,† Yibin Wang, PHD,‡
David A. Kass, MD*
Baltimore, Maryland; and Los Angeles, California
Objectives We tested the hypothesis that bi-directional, gene-targeted regulation of cardiomyocyte cyclic guanosine mono-
phosphate–selective phosphodiesterase type 5 (PDE5) influences maladaptive remodeling in hearts subjected to
sustained pressure overload.
Background PDE5 expression is up-regulated in human hypertrophied and failing hearts, and its inhibition (e.g., by sildenafil)
stimulates protein kinase G activity, suppressing and reversing maladaptive hypertrophy, fibrosis, and contractile
dysfunction. Sildenafil is currently being clinically tested for the treatment of heart failure. However, researchers
of new studies have questioned the role of myocyte PDE5 and protein kinase G (PKG) to this process, proposing
alternative targets and mechanisms.
Methods Mice with doxycycline-controllable myocyte-specific PDE5 gene expression were generated (medium transgenic
[TG] and high TG expression lines) and subjected to sustained pressure overload.
Results Rest myocyte and heart function, histology, and molecular profiling were normal in both TG lines versus controls
at 2 months of age. However, upon exposure to pressure overload (aortic banding), TG hearts developed more
eccentric remodeling, maladaptive molecular signaling, depressed function, and amplified fibrosis with up-
regulation of tissue growth factor signaling pathways. PKG activation was inhibited in TG myocytes versus con-
trols. After establishing a severe cardiomyopathic state, high-TG mice received doxycycline to suppress PDE5
expression/activity only in myocytes. This in turn enhanced PKG activity and reversed all previously amplified
maladaptive responses, despite sustained pressure overload. Sildenafil was also effective in this regard.
Conclusions These data strongly support a primary role of myocyte PDE5 regulation to myocardial pathobiology and PDE5
targeting therapy in vivo and reveal a novel mechanism of myocyte-orchestrated extracellular matrix remodeling
via PDE5/cyclic guanosine monophosphate–PKG regulatory pathways (J Am Coll Cardiol 2010;56:2021–30)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.08.612w
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nd molecular changes often develop from sustained pres-
ure overload and are a major worldwide cause of morbidity
nd mortality. Current treatments target load reduction
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ccepted August 3, 2010.ith diuretics and vasodilators, yet the disease often is
efractory to these approaches. One alternative is to stimu-
ate intrinsic negative regulators of hypertrophy, such as
yclic guanosine monophosphate (cGMP) and its down-
tream protein kinase G (PKG) (1). cGMP levels are
nhanced by nitric oxide (NO) and natriuretic peptides or
See page 2031
y inhibiting cGMP-targeted phosphodiesterases (PDE),
uch as PDE5. The latter is currently used to treat erectile
ysfunction and pulmonary hypertension, yet recent exper-
mental studies show that it also blunts cardiac disease
nduced by ischemia/re-oxygenation (2), pressure-overload
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(5). Such results helped foster the
current National Institutes of
Health –sponsored multicenter
clinical trial (the RELAX [Eval-
uating the Effectiveness of Silde-
nafil at Improving Health Out-
comes and Exercise Ability in
People With Diastolic Heart
Failure] study; NCT00763867)
testing sildenafil in patients with
heart failure and a preserved ejec-
tion fraction.
The mechanisms by which sil-
denafil suppresses and/or reverses
experimental cardiac disease re-
main somewhat controversial.
Recent studies have suggested
hat PDE5 is not the primary target, proposing the more
bundant dual-substrate PDE1 as an alternative (6,7).
urthermore, whether myocyte PDE5 and corresponding
KG regulation modulates cardiac hypertrophy/remodeling
o counter cardiac stress has been recently questioned (6).
larification of this signaling is important because this
ould argue for pursuing alternative molecular targets.
All prior studies in which PDE5 activity was suppressed
mployed inhibitors that are not perfectly selective and that
nfluence multiple cell types. Global gene deletion is em-
ryonically lethal, and successful attempts at conditional
odels have yet to be reported. One alternative model is to
enetically modulate myocyte PDE5 in a bi-directional
anner using a doxycycline (DOX)-responsive alpha myo-
in heavy chain (MHC) promoter-driven overexpression.
p-regulation is relevant as myocardial PDE5 expression/
ctivity rises several-fold in pressure-overload (4) and in
uman cardiac hypertrophy (8) and dilated heart failure (9).
mportantly, the transgene can be selectively re-suppressed
n myocytes after disease is established. Here, we used this
trategy to test the hypothesis that myocyte PDE5 suppres-
ion and associated PKG activation is an important modu-
ator of pressure-overload maladaptation. The results sup-
ort this role and reveal novel cross-talk between myocyte
GMP/PKG and extracellular matrix (ECM) remodeling.
ethods
ardiac-specific PDE5A-inducible transgenic mice.
etracycline-controlled conditional PDE5 mice were gen-
rated by crossing mice expressing PDE5A (tagged with
Flag at the N-terminus) with a modified alpha-MHC
romoter tetracycline-off vector (gift from Jeffrey Robbins)
10) (Fig. 1A) with mice expressing tetracycline transacti-
ator (alpha-MHC promoter). Two founders (sv129x
57BL/6J background) were generated (medium transgenic
me-TG] and high transgenic [hi-TG]), and litter mates
Abbreviations
and Acronyms
cGMP  cyclic guanosine
monophosphate
DOX  doxycycline
ECM  extracellular matrix
LV  left ventricular
MHC  myosin heavy chain
PDE  phosphodiesterase
PKG  protein kinase G
TAC  trans-aortic
constriction
TG  transgenic
TGF  transforming growth
factorxpressing tetracycline transactivator served as controls. dice were born without DOX, so PDE5A was overex-
ressed after birth, but it could be subsequently repressed by
dding DOX (0.5 mg/ml) to drinking water.
ardiac and myocyte functional, biochemical, and molecular
nalyses. These methods and statistical analysis are pro-
ided in detail in the Online Appendix.
esults
ardiac myocyte-specific PDE5 transgenic mice using
etracycline-off induction system. Two independent con-
itional PDE5 overexpression lines were generated (me-
G: 6.7 activity; hi-TG: 10 activity) (Figs. 1B and 1C),
oth born in normal Mendelian ratios and surviving into
dulthood (to 16 months). PDE5 expression in the lung was
nchanged (Online Fig. 1A). Expression of alternative
GMP-PDEs (PDE1, PDE9) was also unchanged in TG
ice (Online Fig. 1B), consistent with unaltered non–
DE5-dependent cGMP-PDE activity (Online Fig. 1C).
ransgene PDE5 localized to myocyte z-disks, similar to
ative protein (11) (Online Fig. 2). Up-regulation of PDE5
ctivity in TG myocytes reduced resting PKG activity
Fig. 1D) 35% (p  0.05) and inhibited stimulated PKG
ctivity (Fig. 1E). The latter was indexed by the lack of
lasma membrane translocation of PKG1-alpha and
KG1-beta in TG myocytes when exposed to cGMP (12).
asal myocyte cGMP was below detection in all models.
esting cardiac chamber and myocyte function is normal
n young adult PDE5-TG mice. Resting phenotype was
omprehensively assessed at age 2 to 3 months. Both
e-TG and hi-TG hearts had normal structural morphol-
gy, myocardial histology, molecular signaling, and left
entricular (LV) function (Online Figs. 3 and 4). LV
yocytes displayed similar resting sarcomere shortening and
esponse to beta-adrenergic stimulation (isoproterenol)
Online Fig. 5). The latter was suppressed by sildenafil,
onsistent with prior reports (11,13) confirming functional
egulation by the transgene protein. In me-TG mice,
ardiac function and histology remained similar to that of
ontrols over 16 months of observation, whereas LV func-
ion declined after 6 months in hi-TG, with hypertrophy
nd interstitial fibrosis documented at 16 months (Online
ig. 3). For subsequent studies of pressure overload with
i-directional myocyte-PDE5 gene regulation, 2- to
-month-old animals were used.
yocyte PDE5 up-regulation worsens cardiac response
o pressure overload. To test the impact of PDE5 up-
egulation on pressure-overload stress, 2-month-old mice
ere subjected to 6 weeks of trans-aortic constriction
TAC). TAC induced concentric and generally compen-
ated hypertrophy in controls; however, both TG lines
isplayed substantial chamber dilation and reduced frac-
ional shortening (Figs. 2A and 2B). Pressure volume
elations confirmed dilation, particularly in hi-TG, and
ontractile depression reflected by load-independent in-
exes. Relaxation rate prolonged only in the TG lines
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lastance) was similar in all TAC groups. Worsened function
as accompanied by hypertrophy at chamber and myocyte
evels, increased heart and lung weight, and interstitial
brosis (Fig. 3). Apoptosis (activated caspase 3) was mini-
al and unaltered after TAC in all groups, and rare positive
ells were interstitial and never myocytes (data not shown).
ack of PKG activation and enhanced maladaptive signaling
athways in TG-TAC hearts. Enhanced myocardial PDE5
ctivity was unaltered in TG myocardium before and after
AC, whereas it rose80% over baseline in controls (about
est level in me-TG) (Fig. 4A). PDE1a-c expression was
naltered after TAC (Online Fig. 6). Basal myocardial
KG activity was similar, reflecting low basal cGMP
Figure 1 Inducible Cardiac-Specific PDE5 Transgenic Mouse M
(A) Schematic of cardiac specific tetracycline (Tet)-off phosphodiesterase-5 (PDE5
of PDE5 expression in myocytes. (C) Myocyte PDE5 activity from 2 founder lines (r
sion level; *p  0.01 vs. control, n  4 to 6 per group). (D) Myocyte protein kina
n  6 to 8 per group). (E) Activation of PKG1 alpha (left) and PKG1 beta (right),
(cGMP), is reflected by rapid translocation to the plasma membrane. This occurred
heavy chain.ynthesis; however, TAC stimulated PKG activity in con- trols by 70%, but not at all in TG myocardium and isolated
yocytes (Fig. 4B). Increased PKG activity despite PDE5
p-regulation after TAC in controls likely reflects a balance
nd compartmentation of cGMP synthesis/hydrolysis (4).
hese data demonstrate that this balance can tilt toward
KG suppression with sufficient PDE5 activity. Protein
xpression of PKG1-alpha and -beta was less in TG at rest,
he latter at a slightly lower weight, suggesting post-
ranslational change. Myocyte gene expression for both
roteins did not change with TAC (Online Fig. 7A);
owever, PKG1-alpha protein levels rose similarly in both
roups, and PKG1-beta increased in TG. Thus reduced
KG activity in TG-TAC hearts could not be attributed to
epressed PKG alpha/beta expression, but rather to post-
genic (TG) system. Two founder lines were developed. (B) Western blot analysis
d as medium transgenic [me-TG] and high transgenic [hi-TG] based on expres-
KG) activity of control and TG group at resting condition (*p  0.05 vs. control,
d green in cardiomyocyte exposed to 8Br–cyclic guanosine monophosphate
ntrol (CON) but not TG myocytes (original magnification 200). MHC  myosinodel
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orsened molecular abnormalities consistent with maladap-
ive hypertrophy over controls. Fetal gene recapitulation
Nppa and Myh7) was more prominent and regulator of
alcineurin-1 (Rcan1, reflecting calcineurin activity) expres-
ion rose more, whereas sarcoplasmic reticulum ATPase
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Figure 2 Exacerbated LV Chamber Dysfunction and Dilation in
(A) Representative echocardiograms and (B) Summary data for fractional shorteni
LV-ESD) (n  3 to 5/group; 2-way analysis of variance p  0.05 for interaction of
weeks). (C) Representative LV pressure-volume (PV) loops and relations show a ri
the end-systolic PV (left upper line) relationship (Ees) reflects contractile function.
increased similarly in all groups. Ees  end-systolic elastance; LVVed  end-diast
maximal LV power divided by EDV; TAC  trans-aortic constriction; Tau  time con
group; p value for 1-way analysis of variance shown for each). *p  0.01 versus c
sham; p  0.05 versus control sham, Kruskal-Wallis test; **p  0.001 versusAtp2a2) and phospholamban (Pln), both key calcium- Fandling proteins, declined more (Fig. 4D). Respective
hanges in protein expression/activation were also ob-
erved (data not shown). Given worsened fibrosis in TG
ice, we determined expression of ECM-regulating genes
Tgfb1,2 and Ctgf). All increased more in TG over con-
rols. Before TAC, their expression was similar (Online
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emodeling. TAC-induced cardiac abnormalities and early
ethality were observed within 1 week in hi-TG mice
Online Figs. 7B and 7C), but not in me-TG mice. This
rovided a model to test the impact of subsequently down-
egulating only cardiomyocyte PDE5. Both controls and
i-TG mice were exposed to 4 weeks of TAC, with DOX
dded to the drinking water after day 7, inhibiting PDE5
ransgene expression in TG mice thereafter. DOX elimi-
ated the disparity in PDE5 activity between groups
Fig. 5A) and PKG activity rose in hi-TG plus DOX,
atching control levels (Fig. 5B). Figure 5C shows echo-
ardiography summary data. After 7 days of TAC, hi-TG
ice displayed worsened function, dilation, and hypertro-
hy. Without subsequent DOX, this progressed further
ver the ensuing 17 days, whereas DOX-treated TG ani-
als displayed recovery to behavior in non-TG controls.
OX treatment did not alter controls.
At 4 weeks of TAC, DOX-treated hi-TG mice had
A
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Figure 3 Chamber, Myocyte, and Molecular Remodeling Induce
(A) Representative cardiac cross-sections (top: hematoxylin and eosin [HE] stain;
(B) Summary data for myocyte cross-sectional area and interstitial fibrosis (analys
weight/tibia length (LW/TL); p  0.005 for 1-way analysis of variance, *p  0.01
weeks; ‡p  0.01 versus CON TAC 6 weeks.imilar LV hypertrophy, fetal gene expression, interstitial cbrosis, and corresponding expression of connective tissue
enes as observed in controls (Figs. 5D, 5E, and 5F). We
lso examined genome-wide modifications in these models
sing microarray analysis. Controls and hi-TG mice had
enerally similar profiles pre-TAC, but transcriptional
hanges after TAC were more pronounced in hi-TG mice.
EGG pathway analysis found greater up-regulation of
ransforming growth factor (TGF) beta, focal adhesion, and
CM receptor interaction genes and reduced oxidative
hosphorylation and metabolic pathway genes (Online
ig. 8). These disparities were largely reversed when PDE5
xpression was reduced by DOX treatment.
Lastly, we compared these results with non–cell-specific
nd less selective inhibition with sildenafil (100 mg/kg/day;
ielding free plasma concentration of 10 to 30 nmol/l, similar
o humans with standard doses). TAC was instituted and
ildenafil started on day 8, by which time hi-TG mice already
isplayed much more hypertrophy and dysfunction, and was
hen continued for 3 weeks. LV function improved and
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middle
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Figure 4 Effect of PDE5 Upregulation on TAC-Stimulated PKG Activity, Calcineurin, and Calcium Cycling Proteins
(A) Myocardial phosphodiesterase-5 (PDE5) activity in controls (CON) versus high-transgenic (hi-TG) mice before and after trans-aortic constriction (TAC) (*p  0.01 vs.
CON, same condition). (B) Myocardial protein kinase G (PKG) activity in CON versus hi-TG mice before and after 6 weeks of TAC (*p  0.05 vs. CON baseline; †p 
0.05 vs. CON TAC 6 weeks); right: isolated myocyte PKG activity determined after 1 week of TAC (*p  0.01 vs. CON, n  3 to 5 in each group. (C) PKG1-alpha and
PKG1-beta protein expression at baseline and after TAC in CON and hi-TG mice. (2-way analysis of variance, *p0.05 vs. CON baseline; **p  0.005 vs. CON baseline;
‡p0.05 vs. hi-TG baseline; †p  0.001 vs. same group baseline). (D) Gene expression assessed by quantitative real-time polymerase chain reaction for regulator of
calcineurin (Rcan1), SERCA2A (Atp2a2), phospholamban (Pln), A-type natriuretic peptide (Nppa), beta-myosin heavy chain (Myh7), tissue growth factor beta-1 and beta-2
(Tgfb1, Tgfb2), and connective tissue growth factor (Ctgf), each normalized to Gapdh. *p  0.01 versus control TAC 6 weeks; †p  0.05 versus control TAC 6 weeks;
‡p  0.01 versus control sham; p  0.05 versus control sham (n  3 to 6 in each group).
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Figure 5 Re-Suppression of Myocyte PDE5 Expression Reverses Established
Maladaptive Cardiac Remodeling Despite Sustained Pressure Overload
Control (CON) and high-transgenic (hi-TG) mice were subjected to 7 days of trans-aortic constriction (TAC), then randomized to either doxycycline (DOX) to suppress phosphodiesterase-5
(PDE5) transgene expression or no treatment, whereas TAC continued for 17 more days. (A) Myocardial PDE5 and (B) protein kinase G (PKG) activity measured in CON and hi-TG at
baseline and at end of study. DOX restored both to levels observed in CON; *p  0.01 versus hi-TG pre-DOX treatment; †p  0.001 versus CON; ‡p  0.01 versus same genotype at
pre-DOX treatment (n  3 to 12/group). (C) Echocardiogram data for DOX reversal study. LV mass  left ventricle mass; other abbreviations are as in Figure 2. All indexes improved in
hi-TG with DOX treatment and becoming indistinguishable from CON values by day 24. *p  0.01 versus CON at same time point and treatment; †p  0.05 versus CON at same time
point and treatment (n  5 to 16). (D) Cardiac hypertrophy assessed by heart weight/tibia length (HW/TL) rose in TG-TAC (end of study), but declined to same level as in CON with DOX
treatment (1-way analysis of variance, p  0.002; *p  0.01 versus CON-TAC; ‡p  0.01 versus hi-TG-TAC. (E) Fetal gene expression (normalized to Gapdh) is similar in CON and hi-TG
TAC groups with DOX treatment. (F) Myocardial fibrosis was exacerbated in hi-TG after TAC without DOX, but fell to CON levels with DOX. Summary data for histological analysis and con-
nective tissue genes (expression shown normalized to CON-TAC, determined at final time point; *p  0.01 vs. CON-TAC; ‡p  0.01 vs. hi-TG TAC).
(
P
c
w
g
t
r
D
T
b
c
E
t
d
r
c
p
S
s
d
s
d
a
i
u
P
C
a
p
t
d
h
g
s
u
h
p
c
s
c
a
s
a
s
s
2028 Zhang et al. JACC Vol. 56, No. 24, 2010
Cardiac Stress Response and Myocyte PDE5 December 7, 2010:2021–30Figs. 6A and 6B), lowering PDE5 activity and enhanced
KG activity (Fig. 6B), all matching levels observed in the
ontrol TAC group. Importantly, sildenafil was applied
hen there was already far more cardiac disease in the TG
roup, so it indeed reversed severity as observed before, and
his occurred despite continued myocyte PDE5 up-
egulation and sustained TAC.
iscussion
he present study addressed the question of whether
i-directional regulation of myocyte PDE5 influences myo-
ardial function and remodeling in hearts subjected to stress.
nhancing PDE5 expression/activity suppressed PKG ac-
ivation and worsened responses to pressure overload in a
ose-dependent manner. Subsequent gene-targeted down-
egulation of myocyte PDE5 reversed pre-established
hamber remodeling and dysfunction despite continued
ressure overload and raised PKG activity to control levels.
imilar reversal was obtained with sildenafil. These data
upport a role for myocyte PDE5 in heart disease and
emonstrate that reduction of such activity in myocytes is
ufficient to observe profound reversal of maladaptive car-
iac stress responses, including cross-talk between myocytes
)%( SF
60
CON-TAC
HITG-TAC
HITG-TAC+SIL
0
20
40
*
* *
D0 D7 D17 D24
PDE5 activity
n.s
1.5
CON TAC hiTG TAC
0
0.5
1
- -
+SIL
A
B
Figure 6 Improvement in Cardiac Function With PDE5 Inhibitor
(A) Data for sham-control, high-transgenic (hi-TG; untreated), and hi-TG plus silden
striction (TAC; pre-treatment), and at days 17 and 24 (10 and 17 days after starti
function observed in untreated hi-TG mice. p  0.01 by 2-way analysis of variance
same time point control (CON)-TAC group; †p  0.01 versus same time point hi-TG
reduced phosphodiesterase-5 (PDE5) activity to levels observed in CON and enhannd the ECM. iResting myocyte PDE5 expression and activity is low;
ndeed some laboratories have detected neither and attrib-
ted the sildenafil effect to its off-target suppression of
DE1 (6,7). PDE1 is a dual-substrate esterase requiring
a2 calmodulin for activation, and although PDE1 block-
de inhibited cell and organ hypertrophy induced by iso-
roterenol in a PKG-dependent manner, this was additive
o effects from PDE5 inhibition, suggesting they regulate
ifferent cGMP pools (14). Ours and other laboratories
ave observed myocyte PDE5 expression (8,9,11,15), and
ene-silencing studies further support the specificity and
electivity of these results (15). Importantly, PDE5 is
p-regulated 2- to 6-fold in experimental mice and human
eart disease (4,7–9), potentially increasing its influence and
harmacologic impact from its subsequent inhibition. In
ontrast, PDE1 changes were small and did not reach
tatistical significance. PDE5 gene up-regulation worsens
ardiac responses to myocardial infarction in experimental
nimals (9), though reversibility was not tested in this prior
tudy. Here we show that myocyte-targeted PDE5 gene up-
nd down-regulation potently re-orients cardiac stress re-
ponses, with the latter indicating that myocyte PDE5
uppression itself confers potent cardiac protective effects.
In addition to expression and activity of PDE5 protein
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December 7, 2010:2021–30 Cardiac Stress Response and Myocyte PDE5yclase activity that provides it substrate, and co-stimulation
f pathways targeted by PKG (or cGMP) signaling. The
yclase most directly involved is soluble guanylate cyclase
oupled to nitric oxide stimulation, as mice with nitric oxide
ynthase (NOS) inhibited or endothelial NOS genetically
eleted lost myocardial modulation by PDE5 inhibitors
11). Both cGMP synthesis and cGMP-PKG targeted
ignaling (such as calcineurin) are stimulated by pathologi-
al stress coupled to G-alpha-q cascades (12,16–18), even as
DE5 is up-regulated, setting the stage whereby subsequent
DE5 inhibition provides greater impact. On the basis of
uch data, we and others have proposed that PDE5 inhibi-
ion acts like a targeted intracellular brake, with minimal
mpact in normal hearts but an enhanced impact in those
nder stress (16,17).
Although sustained PKG activation is traditionally
hought to benefit stressed hearts, direct proof remains
acking (19). Genetic models involving global PKG-1 de-
etion induce early lethality coupled to intestinal dilation
nd malabsorption (20). Recently, Lukowski et al. (6)
tudied mice in which PKG1-beta was overexpressed under
ontrol of the smooth muscle promoter sm22 in mice
lobally lacking both PKG1 (alpha and beta). PKG was
acking in myocytes, yet pressure overload or isoproterenol-
nduced hypertrophy was similar to that of controls, leading
he authors to conclude that myocyte PKG is unimportant
o hypertrophic regulation. The current study provides a
ounterargument in that myocardial (and myocyte) PKG
ctivity was inversely correlated with myocyte PDE5 acti-
ation and maladaptive remodeling after TAC. Several
actors could explain these differences. The model used by
ukowski et al. (6) exhibits striking premature mortality,
hereas even our hi-TG mice had a normal lifespan. In
ddition, disparities in the severity of the hypertrophic stress
nd associated PKG activation, and as well as the nature of
argeted intracellular cGMP/PKG regulation, may have
ontributed.
Cardiac remodeling in response to pressure overload
nvolves complex communication among myocytes, myofi-
roblasts, and vascular cells. Each component informs the
ther of changes in the stress environment, and targeted
ignaling in one compartment can potently impact the
thers (21). One prominent communicator is the cytokine
GF-beta, which is synthesized and has potent activity on
ultiple cell types. Importantly, TGF-beta signaling can be
lunted by PKG by its phosphorylation of Smads at unique
ites to inhibit their nuclear translocation and thereby
ranscriptional activity (22). Atrial natriuretic peptide and
itric oxide block TGF-beta (23,24) and myocyte-secreted
onnective tissue growth factor (25), likely underlying anti-
brotic effects. PDE5 is more highly expressed in myofi-
roblast and vascular cells, and its inhibition in such cells
ather than myocytes has been suggested to underlie the
ardiac effects of sildenafil (6). However, our data reveal that
argeted genetic bi-directional control of myocyte PDE5 isufficient to regulate interstitial fibrosis and associated sig-
aling cascades.
tudy limitations. Several potential study limitations
hould be noted. First, TG models can be subject to
onspecific effects from excessive protein expression. How-
ver, normal cardiac PDE5 expression is low, and its
verexpression still resulted in low levels of protein display-
ng normal subcellular localization and activity in a patho-
hysiologically relevant range. Second, 2-month-old hi-TG
ice had no abnormal molecular profiles, cardiac morphol-
gy, or functional changes, but responded markedly and
dversely to TAC within only a few days. Last, TAC-
nduced changes were reversible with either subsequent
ransgene silencing or sildenafil treatment (maintaining
DE5 overexpression), both despite persistent pressure
verload. Another potential limitation is that our analysis
elied on reversing an overexpression model rather than
sing conditional gene deletion. However, we contend that
AC responses in hi-TG mice rapidly invoked multiple
ascades, and the capacity to broadly reverse these by
argeted gene down-regulation supports the role of myocyte
DE5 and potential role for PDE5 inhibitors in heart
ailure patients.
onclusions
e provide strong support for regulatory control of cardiac
tress remodeling and PKG activity by myocyte PDE5. The
ata counter recent suggestions that neither play a role in
ardiac hypertrophy. Furthermore, we show that myocyte
DE5 modulation can itself suppress fibrosis-related genes
nd fibrosis, highlighting a novel mechanism for myocyte-
rchestrated extracellular matrix remodeling via PDE5/
GMP-PKG regulatory pathways. Reports that PDE5
xpression rises in human heart diseases coupled with the
resent findings that myocyte gene targeting can bi-
irectionally impact maladaptive remodeling responses pro-
ide new insight into the role of this pathway and support
ngoing clinical therapeutic efforts to modulate it.
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